Now Is The Time To Build A Position In Aptevo Therapeutics Inc (NASDAQ:APVO)

Aptevo Therapeutics Inc (NASDAQ:APVO)’s traded shares stood at 1.33 million during the latest session, with the company’s beta value hitting 5.16. At the last check today, the stock’s price was $0.35, to imply a decrease of -3.16% or -$0.01 in intraday trading. The APVO share’s 52-week high remains $21.56, putting it -6060.0% down since that peak but still an impressive 20.0% since price per share fell to its 52-week low of $0.28. The company has a valuation of $3.29M, with an average of 85760.0 shares in intraday trading volume over the past 10 days and average of 5.90 million shares over the past 3 months.

Aptevo Therapeutics Inc (NASDAQ:APVO) trade information

After registering a -3.16% downside in the latest session, Aptevo Therapeutics Inc (APVO) has traded red over the past five days. The 5-day price performance for the stock is 5.79%, and -16.00% over 30 days. With these gigs, the year-to-date price performance is -95.62%. Short interest in Aptevo Therapeutics Inc (NASDAQ:APVO) saw shorts transact 61430.0 shares and set a 0.23 days time to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Aptevo Therapeutics Inc (APVO) estimates and forecasts

Looking at statistics comparing Aptevo Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Aptevo Therapeutics Inc (APVO) shares are -93.08% down over the last 6 months, with its year-to-date growth rate higher than industry average at 93.58% against 17.20%.

Revenue forecast for the current quarter as set by 1.0 analysts is nan. Meanwhile, for the current quarter, a total of 1.0 analyst(s) estimate revenue growth to nan.Earnings reports from the last fiscal year show that sales brought in nan and nan respectively in the corresponding quarters.

APVO Dividends

Aptevo Therapeutics Inc has its next earnings report out on 2024-Nov-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Aptevo Therapeutics Inc (NASDAQ:APVO)’s Major holders

Aptevo Therapeutics Inc insiders hold 0.06% of total outstanding shares, with institutional holders owning 20.85% of the shares at 20.86% float percentage. In total, 20.85% institutions holds shares in the company.

We also have Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Aptevo Therapeutics Inc (APVO) shares. Going by data provided on Jul 31, 2024, Fidelity Extended Market Index Fund holds roughly 19.35 shares. This is just over 0.21% of the total shares, with a market valuation of $6700.0. Data from the same date shows that the other fund manager holds a little less at 2.08, or 0.02% of the shares, all valued at about 721.0.